ArticleCancer medicine2026
Development of a Prognostic Survival Risk Score for Lung Cancer Patients With Type 2 Diabetes Mellitus: A Territory-Wide Retrospective Cohort Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is a leading cause of cancer-related mortality, and its prognosis is often affected by comorbidities such as type 2 diabetes mellitus (T2DM). This study aimed to identify survival risk factors for lung cancer patients with T2DM, evaluate the predictive models, and develop a risk score system for survival prediction. STUDY DESIGN AND
methodsWe analyzed data from 5491 lung cancer patients with T2DM from the Hong Kong Hospital Authority Data Collaboration Laboratory (HADCL) (2000-2020). Prognostic factors were evaluated using Cox proportional hazards regression. Four algorithms were used to construct survival analysis models: Cox proportional hazards regression, LASSO Cox regression, survival tree, and random survival forests (RSF). An interpretable risk scoring system was subsequently derived using the selected predictors.
resultsOlder age at cancer diagnosis, male sex, longer duration between T2DM diagnosis and lung cancer diagnosis (T2DM duration), smoking, alcohol consumption, history of stroke, and higher HbA1c were associated with increased mortality risk, whereas hypertension, coronary heart disease, insulin usage, anti-lipid usage, and anti-diabetic usage were associated with reduced mortality risk. Among the evaluated models, the RSF model demonstrated the best predictive performance, as indicated by the C-index (0.71) and time-dependent AUC (0.883). The developed risk score system included the following criteria: age at cancer diagnosis; T2DM duration; smoking status; HbA1c; HDL-C; serum potassium (K) levels; LDL-C. A score ≥ 75 classified 47.33% of patients as high-risk, with a corresponding five-year survival probability of 5.51%.
conclusionsAmong the evaluated models, the RSF model demonstrated the best predictive performance. The developed risk scoring system may support risk stratification and identification of high-risk patient subgroups, potentially facilitating personalized prognostic assessment and clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.